Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2024 Dec 11.
PMID: 39663448Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy.
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
PMID: 39461876Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
PMID: 38759656Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
PMID: 38656869Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation.
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation. bioRxiv. 2024 Apr 12.
PMID: 38644995Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
PMID: 37507765Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6).
PMID: 37385724Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 08; 189:112923.
PMID: 37301715Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
PMID: 36595378Tissue-resident memory T cells in immune-related adverse events: friend or foe?
View All Publications
Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358.
PMID: 37035636
People
Thomas F. Gajewski, MD PhD
-
AbbVie Foundation Professor of Pathology
Professor of Ben May Department of Cancer Research
Professor of Medicine
Committee on Cancer Biology
Committee on Clinical Pharmacology and Pharmacogenomics - Clinical Interests: Immunotherapy, Melanoma
- Websites: Research Network Profile
- Contact: tgajewsk@medicine.bsd.uchicago.edu
- Graduate Programs: Cancer Biology, UChicago Biosciences, Committee on Immunology